Panacea Biotec Limited (BOM:531349)
India · Delayed Price · Currency is INR 410.40
-3.65 (-0.88%)
At close: Aug 21, 2026
Panacea Biotec Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -53.7 | -83.7 | -11.73 | -332.37 | 10,783 |
Depreciation & Amortization | 330.6 | 324.58 | 344.31 | 388.61 | 430.34 |
Other Amortization | - | 23.56 | 22.8 | 2.62 | 7.43 |
Loss (Gain) From Sale of Assets | - | -4.46 | 45.59 | -22.99 | -0.07 |
Asset Writedown & Restructuring Costs | 1.3 | 13.95 | 51.57 | - | 15.75 |
Loss (Gain) From Sale of Investments | - | -24.5 | -33.67 | - | - |
Provision & Write-off of Bad Debts | 35.2 | 13.29 | 5.66 | 23.87 | 8.98 |
Other Operating Activities | -286.3 | -450.6 | -492.17 | -915.15 | -15,339 |
Change in Accounts Receivable | 12.8 | -158.42 | 29.56 | 68.94 | -463.4 |
Change in Inventory | 208.8 | -357.36 | 241.58 | 106.3 | -385.8 |
Change in Other Net Operating Assets | -81.9 | 429.97 | -168.82 | -3,544 | 3,858 |
Operating Cash Flow | 166.8 | -273.69 | 34.68 | -4,225 | -1,084 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -540.9 | -503.05 | -828.76 | -409.46 | -125.1 |
Sale of Property, Plant & Equipment | - | 5.75 | 66.83 | 395.05 | 20 |
Divestitures | - | - | - | - | 18,220 |
Investment in Securities | 64.8 | 1,029 | 695.15 | 4,197 | -5,322 |
Other Investing Activities | 71.2 | 117.84 | 133.37 | 120.62 | 32.8 |
Investing Cash Flow | -404.9 | 649.84 | 66.59 | 4,303 | 12,826 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Long-Term Debt Issued | - | - | - | - | 2.96 |
Total Debt Issued | - | - | - | - | 2.96 |
Long-Term Debt Repaid | - | - | -2.36 | -147.74 | -7,864 |
Total Debt Repaid | - | - | -2.36 | -147.74 | -7,864 |
Net Debt Issued (Repaid) | - | - | -2.36 | -147.74 | -7,861 |
Other Financing Activities | -10.5 | -26.64 | -25.72 | -35.99 | -3,898 |
Financing Cash Flow | -10.5 | -26.64 | -28.08 | -183.73 | -11,759 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Foreign Exchange Rate Adjustments | 0.4 | - | 0.03 | -0.04 | -0.13 |
Net Cash Flow | -248.2 | 349.51 | 73.22 | -104.98 | -17.42 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -374.1 | -776.74 | -794.08 | -4,634 | -1,210 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -5.85% | -13.89% | -14.20% | -100.75% | -18.29% |
Free Cash Flow Per Share | -6.13 | -12.68 | -12.96 | -75.66 | -19.75 |
Levered Free Cash Flow | -895.29 | -741.96 | -753.09 | -4,293 | 2,811 |
Unlevered Free Cash Flow | -857.48 | -723.69 | -736.38 | -4,269 | 3,935 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 44.2 | 26.64 | 25.72 | 35.99 | 3,898 |
Cash Income Tax Paid | 64.5 | 9.69 | 25.06 | 24.77 | 4,037 |
Change in Working Capital | 139.7 | -85.81 | 102.32 | -3,369 | 3,009 |